2.1. Inhibition of both VEGFR2 and IGF1R Potentiate the Effects on Cell Growth Deriving from the Combination of Regorafenib/Sorafenib in HCC Cell Lines. This evidence concerns the gene KDR and hepatocellular carcinoma.